VEGF, VEGFR2 and GSTM1 Polymorphisms in Outcome of Multiple Myeloma Patients Treated with Thalidomide-based Regimens

Overview

Journal Blood Cancer J

Date 2017 Jul 1

PMID 28665417

Citations 3

Authors

L Lopes-Aguiar

M T Delamain

A B C Brito

G J Lourenco

E F D Costa

G B Oliveira

J Vassallo

C A De Souza

C S P Lima

Affiliations

Soon will be listed here.

Citing Articles

Integrated network pharmacology and experimental verification to explore the potential mechanism of San Ying decoction for treating triple-negative breast cancer.

Yang X, Li F, Shi Y, Wu Y, Yang R, Liu X Acta Biochim Biophys Sin (Shanghai). 2024; 56(5):763-775.

PMID: 38516703 PMC: 11177106. DOI: 10.3724/abbs.2024015.

Direct reprogramming of human smooth muscle and vascular endothelial cells reveals defects associated with aging and Hutchinson-Gilford progeria syndrome.

Bersini S, Schulte R, Huang L, Tsai H, Hetzer M Elife. 2020; 9.

PMID: 32896271 PMC: 7478891. DOI: 10.7554/eLife.54383.

The Association of , and α Polymorphisms With the Risk and Outcome in Multiple Myeloma.

Zmorzynski S, Popek-Marciniec S, Szudy-Szczyrek A, Wojcierowska-Litwin M, Korszen-Pilecka I, Chocholska S Front Oncol. 2019; 9:1056.

PMID: 31681592 PMC: 6798955. DOI: 10.3389/fonc.2019.01056.

References

Lourenco G, Lorand-Metze I, Delamain M, Miranda E, Kameo R, Metze K . Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma. 2010; 51(12):2215-21. DOI: 10.3109/10428194.2010.527402. View

Shahbazi M, Fryer A, Pravica V, Brogan I, Ramsay H, Hutchinson I . Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2001; 13(1):260-264. DOI: 10.1681/ASN.V131260. View

Medeiros R, Soares R, Vasconcelos A, Schmitt F, Lopes C . Glutathione S-transferase genotype GSTM1 as a predictor of elevated angiogenic phenotype in patients with early onset breast cancer. Angiogenesis. 2004; 7(1):53-8. DOI: 10.1023/B:AGEN.0000037330.20121.d8. View

Andersen N, Vogel U, Klausen T, Gimsing P, Gregersen H, Abildgaard N . Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer. 2011; 131(5):E636-42. DOI: 10.1002/ijc.27387. View

Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y . Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol. 2007; 50(8):760-7. DOI: 10.1016/j.jacc.2007.04.074. View

Markovic O, Marisavljevic D, Cemerikic V, Vidovic A, Perunicic M, Todorovic M . Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance. Med Oncol. 2008; 25(4):451-7. DOI: 10.1007/s12032-008-9066-y. View

Hayes J, Flanagan J, Jowsey I . Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005; 45:51-88. DOI: 10.1146/annurev.pharmtox.45.120403.095857. View

Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A . Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009; 69(12):5082-90. DOI: 10.1158/0008-5472.CAN-08-4603. View

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E . A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2001; 37(6):443-8. DOI: 10.1159/000054076. View

10.

Watson C, WEBB N, Bottomley M, Brenchley P . Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000; 12(8):1232-5. DOI: 10.1006/cyto.2000.0692. View

11.

Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M . Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica. 2007; 92(8):1075-82. DOI: 10.3324/haematol.11208. View

12.

de Mendonca G, Brito A, Rocha R, Delamain M, de Andrade Natal R, Soares F . Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients. Blood Cancer J. 2016; 6(8):e464. PMC: 5022185. DOI: 10.1038/bcj.2016.76. View

13.

Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P . Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica. 2007; 92(2):277-8. DOI: 10.3324/haematol.10618. View

14.

Rajkumar S, Kumar S . Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc. 2016; 91(1):101-19. PMC: 5223450. DOI: 10.1016/j.mayocp.2015.11.007. View

15.

Bhaskar A, Gupta R, Sreenivas V, Rani L, Kumar L, Sharma A . Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leuk Res. 2013; 37(4):410-5. DOI: 10.1016/j.leukres.2012.12.014. View